Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Phase 1/1b Study of ORIC-944 as a Single Agent or in Combination With an Androgen Receptor Pathway Inhibitor in Patients With Metastatic Prostate Cancer

NCT05413421 is registered in ClinicalTrials.gov with ORIC Pharmaceuticals as lead sponsor.

NCT NCT05413421
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05413421 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Phase 1/1b Study of ORIC-944 as a Single Agent or in Combination With an Androgen Receptor Pathway Inhibitor in Patients With Metastatic Prostate Cancer
Lead sponsor
ORIC Pharmaceuticals
Phase
Phase 1
Overall status
Recruiting
Start date
June 1, 2022
Completion date
April 30, 2028
Enrollment
275 (estimated)
Sites
27

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic prostate cancer